Department of Medicine, Division of Metabolism, Endocrinology and Nutrition and Department of Laboratory Medicine and Pathology, University of Washington Medicine Diabetes Institute, Seattle.
Arterioscler Thromb Vasc Biol. 2022 Jul;42(7):819-830. doi: 10.1161/ATVBAHA.122.317163. Epub 2022 May 26.
Both type 1 and type 2 diabetes are associated with an increased risk of atherosclerotic cardiovascular disease (CVD). Research based on human-first or bedside-to-bench approaches has provided new insights into likely mechanisms behind this increased risk. Although both forms of diabetes are associated with hyperglycemia, it is becoming increasingly clear that altered lipoprotein metabolism also plays a critical role in predicting CVD risk in people with diabetes. This review examines recent findings indicating that increased levels of circulating remnant lipoproteins could be a missing link between diabetes and CVD. Although CVD risk associated with diabetes is clearly multifactorial in nature, these findings suggest that we should increase efforts in evaluating whether remnant lipoproteins or the proteins that govern their metabolism are biomarkers of incident CVD in people living with diabetes and whether reducing remnant lipoproteins will prevent the increased CVD risk associated with diabetes.
1 型和 2 型糖尿病均与动脉粥样硬化性心血管疾病(CVD)风险增加相关。基于以人为本或床旁到临床的方法的研究为这种风险增加背后的可能机制提供了新的见解。虽然两种类型的糖尿病都与高血糖有关,但越来越明显的是,脂蛋白代谢的改变也在预测糖尿病患者的 CVD 风险方面发挥着关键作用。本综述探讨了最近的发现,表明循环残粒脂蛋白水平升高可能是糖尿病与 CVD 之间缺失的一环。虽然与糖尿病相关的 CVD 风险显然是多因素的,但这些发现表明,我们应该加大努力评估残粒脂蛋白或控制其代谢的蛋白质是否是糖尿病患者发生 CVD 的生物标志物,以及降低残粒脂蛋白是否会预防与糖尿病相关的 CVD 风险增加。